Skip to content

Kodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business Highlights

PALO ALTO, Calif., Aug. 9, 2021 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the second quarter ended June 30, 2021. “The Kodiak team continued its strong execution across our clinical, regulatory and pipeline objectives in the … Continued

Kodiak Sciences Announces First Quarter 2021 Financial Results and Recent Business Highlights

PALO ALTO, Calif., May 10, 2021 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the first quarter ended March 31, 2021. “Developing and launching a novel anti-VEGF medicine with extended durability is the central principle of our … Continued

Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

PALO ALTO, Calif., March 1, 2021 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended December 31, 2020. “Our Phase 1b data show two in every three patients are on a 6-month or longer … Continued

Kodiak Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet AMD, DME and RVO at Angiogenesis 2021

– 2 in every 3 patients are on a 6-month or longer treatment-free interval at Year 1 in each of the 3 major retinal vascular diseases, wAMD, DME and RVO, after only 3 loading doses– 78% of patients with wAMD, 84% with DME and 75% with RVO are on a 4-month or longer treatment interval … Continued

Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced the closing of its previously announced underwritten public offering of 5,972,222 shares of its common stock, which includes 778,985 shares sold pursuant to the underwriters’ exercise in … Continued

Kodiak Sciences to Present at the J.P. Morgan Healthcare Conference

PALO ALTO, Calif., Jan. 5, 2021 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the virtual J.P. Morgan Healthcare Conference on Monday January 11, 2021 at 11:50 a.m. Pacific Time (2:50 p.m. Eastern Time). A live webcast of the presentation will be … Continued

Kodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stock

Download PDF PALO ALTO, Calif., Nov. 17, 2020 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced the pricing of an underwritten public offering of 5,193,237 shares of its common stock at a price to the public of $108.00 per share. The aggregate gross … Continued

Kodiak Sciences Announces Third Quarter 2020 Financial Results and Recent Business Highlights

PALO ALTO, Calif., Nov. 9, 2020 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the third quarter ended September 30, 2020. “We continue our strong execution in this second half of 2020,” said Victor Perlroth, MD, Chief … Continued

Kodiak Sciences Treats First Patients in Three Ph. 3 Studies of KSI-301 – Two Studies in DME and One Study in Macular Edema Due to RVO

– Concurrent development program compares Kodiak’s long-acting anti-VEGF antibody biopolymer conjugate KSI-301 to standard of care in all major retinal disease indications: wet AMD, DME, and RVO.– Kodiak also announces completion of U.S. patient enrollment in DAZZLE, its ongoing Phase 2b/3 study of KSI-301 in wet AMD.– Phase 1b durability data continue to improve as … Continued

Lonza’s Ibex Dedicate to Support the Commercial Manufacture of Kodiak’s KSI-301 – an Antibody Biopolymer Conjugate for Retinal Diseases

•  Purpose-built bioconjugation facility in Lonza’s Ibex™ Dedicate Biopark to support the potential commercial launch of Kodiak’s leading ophthalmic therapeutic candidate KSI-301 with a capacity to supply millions of doses per year •  Provides accelerated build-time and flex up and flex down capabilities with facility construction targeted for completion from end 2021 •  The agreement also integrates Kodiak’s … Continued